Search

Search Constraints

You searched for: Author/Creator Bouche, Olivier

Search Results

2. Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. Issue 3 (March 2021)

3. Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE 22 phase II randomized multicentre trial. (10th March 2021)

4. Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. (July 2017)

5. Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial' [European Journal of Cancer, Volume 124 (January 2020) Pages 91-101]. (May 2020)

6. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. (January 2020)

7. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX‐bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study. Issue 11 (14th July 2022)

8. Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Issue 9 (September 2019)

9. Identification of circulating biomarkers of Crohn's disease and spondyloarthritis using Fourier transform infrared spectroscopy. Issue 2 (30th September 2022)

10. Incidental gastrointestinal 18F-Fluorodeoxyglucose uptake associated with lung cancer. Issue 1 (December 2015)